These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22789497)

  • 1. Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.
    Kurbatova EV; Taylor A; Gammino VM; Bayona J; Becerra M; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Viiklepp P; Zignol M; Cegielski JP
    Tuberculosis (Edinb); 2012 Sep; 92(5):397-403. PubMed ID: 22789497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projects.
    Gammino VM; Taylor AB; Rich ML; Bayona J; Becerra MC; Bonilla C; Gelmanova I; Hollo V; Jaramillo E; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riektsina V; Tupasi TE; Wells CD; Zignol M; Cegielski PJ
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1315-22. PubMed ID: 22283887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.
    Nathanson E; Gupta R; Huamani P; Leimane V; Pasechnikov AD; Tupasi TE; Vink K; Jaramillo E; Espinal MA
    Int J Tuberc Lung Dis; 2004 Nov; 8(11):1382-4. PubMed ID: 15581210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
    Kliiman K; Altraja A
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multidrug-resistant tuberculosis management in resource-limited settings.
    Nathanson E; Lambregts-van Weezenbeek C; Rich ML; Gupta R; Bayona J; Blöndal K; Caminero JA; Cegielski JP; Danilovits M; Espinal MA; Hollo V; Jaramillo E; Leimane V; Mitnick CD; Mukherjee JS; Nunn P; Pasechnikov A; Tupasi T; Wells C; Raviglione MC
    Emerg Infect Dis; 2006 Sep; 12(9):1389-97. PubMed ID: 17073088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study.
    Leimane V; Riekstina V; Holtz TH; Zarovska E; Skripconoka V; Thorpe LE; Laserson KF; Wells CD
    Lancet; 2005 Jan 22-28; 365(9456):318-26. PubMed ID: 15664227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.
    Cavanaugh JS; Kazennyy BY; Nguyen ML; Kiryanova EV; Vitek E; Khorosheva TM; Nemtsova E; Cegielski JP
    Int J Tuberc Lung Dis; 2012 Aug; 16(8):1069-74. PubMed ID: 22691694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia.
    Riekstina V; Leimane V; Holtz TH; Leimans J; Wells CD
    Int J Tuberc Lung Dis; 2007 May; 11(5):585-7. PubMed ID: 17439686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently needed.
    Tupasi TE; Quelapio MI; Orillaza RB; Alcantara C; Mira NR; Abeleda MR; Belen VT; Arnisto NM; Rivera AB; Grimaldo ER; Derilo JO; Dimarucut W; Arabit M; Urboda D
    Tuberculosis (Edinb); 2003; 83(1-3):52-8. PubMed ID: 12758189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment outcomes in an integrated civilian and prison MDR-TB treatment program in Russia.
    Shin SS; Pasechnikov AD; Gelmanova IY; Peremitin GG; Strelis AK; Mishustin S; Barnashov A; Karpeichik Y; Andreev YG; Golubchikova VT; Tonkel TP; Yanova GV; Nikiforov M; Yedilbayev A; Mukherjee JS; Furin JJ; Barry DJ; Farmer PE; Rich ML; Keshavjee S
    Int J Tuberc Lung Dis; 2006 Apr; 10(4):402-8. PubMed ID: 16602404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment.
    Kurbatova EV; Gammino VM; Bayona J; Becerra M; Danilovitz M; Falzon D; Gelmanova I; Keshavjee S; Leimane V; Mitnick CD; Quelapio MI; Riekstina V; Taylor A; Viiklepp P; Zignol M; Cegielski JP
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1553-5, i. PubMed ID: 22008772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of treating multidrug-resistant tuberculosis.
    Resch SC; Salomon JA; Murray M; Weinstein MC
    PLoS Med; 2006 Jul; 3(7):e241. PubMed ID: 16796403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors and mortality associated with default from multidrug-resistant tuberculosis treatment.
    Franke MF; Appleton SC; Bayona J; Arteaga F; Palacios E; Llaro K; Shin SS; Becerra MC; Murray MB; Mitnick CD
    Clin Infect Dis; 2008 Jun; 46(12):1844-51. PubMed ID: 18462099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study.
    Bulabula ANH; Nelson JA; Musafiri EM; Machekano R; Sam-Agudu NA; Diacon AH; Shah M; Creswell J; Theron G; Warren RM; Jacobson KR; Chirambiza JP; Kalumuna D; Bisimwa BC; Katoto PDMC; Kaswa MK; Birembano FM; Kitete L; Grobusch MP; Kashongwe ZM; Nachega JB
    Clin Infect Dis; 2019 Sep; 69(8):1278-1287. PubMed ID: 30759187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant tuberculosis among previously treated patients in the Philippines.
    Gler MT; Macalintal LE; Raymond L; Guilatco R; Quelapio MI; Tupasi TE
    Int J Tuberc Lung Dis; 2011 May; 15(5):652-6. PubMed ID: 21756517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decline in rates of acquired multidrug-resistant tuberculosis after implementation of the directly observed therapy, short course (DOTS) and DOTS-Plus programmes in Taiwan.
    Chien JY; Lai CC; Tan CK; Chien ST; Yu CJ; Hsueh PR
    J Antimicrob Chemother; 2013 Aug; 68(8):1910-6. PubMed ID: 23580558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
    Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
    Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
    van den Hof S; Tursynbayeva A; Abildaev T; Adenov M; Pak S; Bekembayeva G; Ismailov S
    Int J Tuberc Lung Dis; 2013 Apr; 17(4):526-31. PubMed ID: 23485387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline Predictors of Treatment Outcomes in Children With Multidrug-Resistant Tuberculosis: A Retrospective Cohort Study.
    Chiang SS; Starke JR; Miller AC; Cruz AT; Del Castillo H; Valdivia WJ; Tunque G; García F; Contreras C; Lecca L; Alarcón VA; Becerra MC
    Clin Infect Dis; 2016 Oct; 63(8):1063-71. PubMed ID: 27458026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.